Other equities analysts have also recently issued research reports about the stock. Deutsche Bank AG cut shares of Imperva from a buy rating to a hold rating and reduced their price target for the company from $45.00 to $43.00 in a research report on Tuesday, July 12th. BTIG Research reiterated a buy rating and set a $55.00 price target on shares of Imperva in a research report on Monday, July 11th. Needham & Company LLC restated a hold rating on shares of Imperva in a report on Tuesday, July 12th. Royal Bank Of Canada cut their price objective on shares of Imperva from $55.00 to $49.00 and set an outperform rating on the stock in a report on Tuesday, July 12th. Finally, JPMorgan Chase & Co. restated a hold rating and issued a $46.00 price objective on shares of Imperva in a report on Friday, August 5th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $53.33.
Shares of Imperva (NYSE:IMPV) opened at 53.18 on Monday. The stock’s 50 day moving average is $46.58 and its 200 day moving average is $44.39. The stock’s market cap is $1.73 billion. Imperva has a 52 week low of $31.11 and a 52 week high of $77.99.
Imperva (NYSE:IMPV) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.19. Imperva had a negative net margin of 23.75% and a negative return on equity of 25.68%. The company had revenue of $57.87 million for the quarter, compared to analysts’ expectations of $66.06 million. During the same quarter in the prior year, the firm earned ($0.08) EPS. Imperva’s quarterly revenue was up 8.2% compared to the same quarter last year. On average, equities analysts forecast that Imperva will post ($0.80) EPS for the current year.
In other news, insider Amichai Shulman sold 3,085 shares of the stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $46.28, for a total value of $142,773.80. Following the completion of the sale, the insider now directly owns 93,380 shares of the company’s stock, valued at $4,321,626.40. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Mark E. Kraynak sold 5,582 shares of the stock in a transaction on Friday, September 23rd. The stock was sold at an average price of $51.00, for a total transaction of $284,682.00. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by company insiders.
Several hedge funds have recently made changes to their positions in the company. Royal Bank of Canada boosted its stake in shares of Imperva by 11.4% in the second quarter. Royal Bank of Canada now owns 5,457 shares of the company’s stock worth $235,000 after buying an additional 558 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in shares of Imperva by 6.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 97,461 shares of the company’s stock worth $4,192,000 after buying an additional 5,914 shares during the period. Stifel Financial Corp boosted its stake in shares of Imperva by 4.1% in the second quarter. Stifel Financial Corp now owns 76,685 shares of the company’s stock worth $3,298,000 after buying an additional 3,034 shares during the period. Elk Creek Partners LLC boosted its stake in shares of Imperva by 124.9% in the second quarter. Elk Creek Partners LLC now owns 343,824 shares of the company’s stock worth $14,788,000 after buying an additional 190,955 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Imperva by 10.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 20,500 shares of the company’s stock worth $882,000 after buying an additional 1,892 shares during the period. 93.26% of the stock is owned by hedge funds and other institutional investors.
Imperva Company Profile
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.
Receive News & Ratings for Imperva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.